tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AZNCF Stock Latest News

AstraZeneca says to end U.S. commercial sales of Andexxa
The FlyAstraZeneca says to end U.S. commercial sales of Andexxa
4d ago
AZN
Government deals lift overhang on pharma group, says BofA
PremiumThe Fly
Government deals lift overhang on pharma group, says BofA
4d ago
AZN
BMY
AstraZeneca trial of docetaxel, Imfinzi did not meet primary endpoint of OS
PremiumThe Fly
AstraZeneca trial of docetaxel, Imfinzi did not meet primary endpoint of OS
4d ago
AZN
AstraZeneca Discloses Routine Share Sale by Non-Executive Director
PremiumCompany Announcements
AstraZeneca Discloses Routine Share Sale by Non-Executive Director
4d ago
AstraZeneca, Daiichi Sankyo granted breakthrough therapy designation for Enhertu
PremiumThe Fly
AstraZeneca, Daiichi Sankyo granted breakthrough therapy designation for Enhertu
4d ago
AZN
AstraZeneca, Daiichi Sankyo dose firs patient in DESTINY-Endometrial02 trial
PremiumThe FlyAstraZeneca, Daiichi Sankyo dose firs patient in DESTINY-Endometrial02 trial
4d ago
AZN
Enhertu Wins US Breakthrough Status in High‑Risk Early HER2‑Positive Breast Cancer
Premium
Company Announcements
Enhertu Wins US Breakthrough Status in High‑Risk Early HER2‑Positive Breast Cancer
4d ago
AstraZeneca’s LATIFY Lung Cancer Trial of Ceralasertib–Imfinzi Combo Misses Survival Goal
Premium
Company Announcements
AstraZeneca’s LATIFY Lung Cancer Trial of Ceralasertib–Imfinzi Combo Misses Survival Goal
4d ago
Drugmakers set to make deals with Trump in exchange for incentives, WaPo reports
PremiumThe Fly
Drugmakers set to make deals with Trump in exchange for incentives, WaPo reports
7d ago
AZN
BMY
AstraZeneca Discloses Director’s Gift of Shares to Spouse
PremiumCompany Announcements
AstraZeneca Discloses Director’s Gift of Shares to Spouse
7d ago
Niowave expands global supply agreement with AstraZeneca for Actinium-225
PremiumThe Fly
Niowave expands global supply agreement with AstraZeneca for Actinium-225
8d ago
AZN
AstraZeneca, Daiichi Sankyo get EMA validation of Datroway Type II Variation MAA
PremiumThe Fly
AstraZeneca, Daiichi Sankyo get EMA validation of Datroway Type II Variation MAA
8d ago
AZN
Compugen and AstraZeneca agree to monetize rilvegostomig future royalties
PremiumThe FlyCompugen and AstraZeneca agree to monetize rilvegostomig future royalties
9d ago
AZN
CGEN
AstraZeneca’s Saphnelo approved in EU for subcutaneous self-admin
Premium
The Fly
AstraZeneca’s Saphnelo approved in EU for subcutaneous self-admin
10d ago
AZN
AstraZeneca’s Saphnelo Gains EU Approval for Self-Administration in Lupus Treatment
Premium
Company Announcements
AstraZeneca’s Saphnelo Gains EU Approval for Self-Administration in Lupus Treatment
10d ago
AstraZeneca’s Enhertu Approved for HER2-Positive Breast Cancer
PremiumCompany Announcements
AstraZeneca’s Enhertu Approved for HER2-Positive Breast Cancer
10d ago
AstraZeneca says Enhertu plus pertuzumab approved by FDA for 1st line treatment
PremiumThe Fly
AstraZeneca says Enhertu plus pertuzumab approved by FDA for 1st line treatment
10d ago
AZN
AstraZeneca confirms FDA approves Enhertu combo for certain breast cancers
PremiumThe Fly
AstraZeneca confirms FDA approves Enhertu combo for certain breast cancers
11d ago
AZN
FDA approves Enhertu with pertuzumab for certain HER2-positive breast cancer
PremiumThe Fly
FDA approves Enhertu with pertuzumab for certain HER2-positive breast cancer
11d ago
AZN
AstraZeneca price target raised to $108 from $95 at HSBC
PremiumThe FlyAstraZeneca price target raised to $108 from $95 at HSBC
16d ago
AZN
AstraZeneca price target raised to $105 from $95 at TD Cowen
Premium
The Fly
AstraZeneca price target raised to $105 from $95 at TD Cowen
17d ago
AZN
AstraZeneca, Daiichi Sankyo dose first patient in DESTINY-Ovarian01 trial
Premium
The Fly
AstraZeneca, Daiichi Sankyo dose first patient in DESTINY-Ovarian01 trial
17d ago
AZN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >